Neuromodulation continued to face a challenging macro environment in Q322 related to stubborn inflationary pressures, currency exchange headwinds and unpredictable surges in COVID affecting supply chains and healthcare staffing in certain geographies. However, some competitors reported seeing steady signs of improvement in the quarter and are looking to expanded indications and new technologies to help drive growth.
Among the many topics covered in detail in our comprehensive Q322 Neuromodulation Market Recap* are:
Although all the competitors in the US SCS market saw positive YoY revenue growth in Q322, the WW market was flat YoY and the overall market remains soft as companies struggle to reach pre-pandemic revenue levels. The US SCS market reached revenues of ...
Read the entire Q322 Neuromodulation Market Recap, including SmartTRAK's expert analysis, news, data, charts, company revenues and shares*
*The complete unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.